Investigational drug · Phase 3
Hemay005
Also called: Mufemilast, Phosphodiesterase 4 inhibitors, PDE4, Hemay005 group
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease).
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
21
Any phase or sponsor naming "Hemay005"
First trial start
2022
Nov 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Hemay005", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Moderate to Severe Ulcerative Colitis
- Ulcerative Colitis (UC)
- COPD (Chronic Obstructive Pulmonary Disease)
- Behçet's Disease
Approved drugs for the same conditions: Ulcerative colitis · COPD · Immunology and inflammation · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Hemay005" as an intervention, largest first.
- Evaluation the Safety of hemay005 TabletsPivotal-lookingCompleted
Anhui Hemay Pharmaceutical Co., LtdIndustry
NCT06908642 · 468 participants · Start Dec 25, 2024 · Primary completion Jun 3, 2025
Drug: Hemay005 tablet; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Wuhu, China
- Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative ColitisPivotal-lookingNot yet recruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT07650942 · 360 participants (planned) · Start Jun 2026 · Primary completion May 2028
Drug: Hemay005 tablet; Placebo and 2 more · For: Ulcerative Colitis (UC)
Sites: Guangzhou, China · 2 sites in all
- A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Tianjin Hemay Pharmaceutical Co., LtdIndustry
NCT04839328 · 306 participants · Start Jan 20, 2022 · Primary completion Oct 25, 2022
Drug: 60mg Hemay005; Placebo · For: Psoriasis
Sites: Beijing, China
- Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Tianjin Hemay Pharmaceutical Co., LtdIndustry
NCT04102241 · 216 participants · Start May 30, 2019 · Primary completion Oct 12, 2020
Drug: 15mg Hemay005; Placebos · For: Psoriasis
Sites: Hangzhou, China
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseasePivotal-lookingRecruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT06145893 · 162 participants (planned) · Start Nov 13, 2023 · Primary completion May 30, 2026
Drug: Hemay005; Hemay005 and 1 more · For: Behçet's Disease
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 22 sites in all
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPDPivotal-lookingNot yet recruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT07314242 · 120 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2027
Drug: Hemay005 tablets; Roflumilast Oral Tablet and 1 more · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Tianjin, China · 2 sites in all
- Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisActive, not recruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT05486104 · 92 participants · Start Nov 8, 2022 · Primary completion Dec 30, 2026
Drug: Hemay005 tablets; Hemay005 placebo tablets · For: Moderate to Severe Ulcerative Colitis
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 18 sites in all
Tianjin Hemay Pharmaceutical Co., LtdIndustry
NCT05407246 · 90 participants · Start Aug 5, 2022 · Primary completion Aug 18, 2023
Drug: Hemay005 · For: Active Ankylosing Spondylitis
Sites: Hefei, China; Beijing, China; Guangzhou, China · 11 sites in all
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminated
Tianjin Hemay Pharmaceutical Co., LtdIndustry
NCT04609397 · 89 participants · Start Nov 30, 2020 · Primary completion Apr 30, 2022
Drug: Hemay005; Hemay005 · For: Behçet Disease
Sites: Bengbu, China; Hefei, China; Beijing, China · 31 sites in all
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT05769946 · 79 participants · Start Nov 24, 2022 · Primary completion Jan 24, 2024
Drug: Hemay005 · For: Hemay005, Atopic Dermatitis
Sites: Shijiazhuang, China
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of phosphodiesterase inhibitors in neural cell models for the development of functionalized chitosan microstructured films as scaffolds for peripheral nerve regeneration.
Fregnan F, Scaccini L, El Soury M, et al. · Biomater Adv 2027
- Phosphodiesterase 4 inhibitors extend lifespan of C. elegans and attenuate cellular senescence of mouse embryonic fibroblasts.
Wang ZY, Zhao XJ, Gao S, et al. · Free Radic Biol Med 2026
- Ensifentrine inhibits lipopolysaccharide-induced production of cytokines by human lung macrophages: a comparison with roflumilast, and an interaction with adenosine.
Brollo M, Salvator H, Glorion M, et al. · Int Immunopharmacol 2026
- Efficacy and safety of crisaborole ointment combined with 308-nm excimer laser in the treatment of non-segmental vitiligo: a randomized, intra-patient left-right controlled study protocol.
Pan D, Wu Y, Wu H, et al. · J Dermatolog Treat 2026
- Increased CD39⁺CD4⁺ T cells during apremilast therapy: considerations regarding predictive value and functional significance.
Yao S, Xu D · Rheumatol Int 2026
- Anti-Inflammatory and Antifibrotic Effects of Hyaluronidase Versus a Phosphodiesterase Type 4 Inhibitor in C57BL/6 Mice with Emphysema.
Ermakova NN, Pan ES, Zhukova MA, et al. · Bull Exp Biol Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.